News — heart failure supplements
Beyond Blood Sugar: SGLT2 Inhibitors Redefining Heart Failure Treatment
canagliflozin cardio-renal health CardioSupport Matrix cardiovascular outcomes dapagliflozin diabetes and heart disease diuresis in heart failure empagliflozin glucose and heart health heart failure supplements heart failure treatment heart medication HFpEF HFrEF ketones and cardiac energy modern cardiology preserved ejection fraction reduced ejection fraction renal protection SGLT2 inhibitors SGLT2 mechanism
Once viewed solely as glucose-lowering agents for people with type 2 diabetes, SGLT2 inhibitors are now at the forefront of a revolution in cardiology. These medications—originally developed to reduce blood sugar by promoting glucose excretion through the urine—have unexpectedly emerged as powerful tools in the management of heart failure, offering benefits that extend far beyond glycemic control.
Today, SGLT2 inhibitors like empagliflozin, dapagliflozin, and canagliflozin are being prescribed for patients with and without diabetes to treat heart failure with both reduced and preserved ejection fraction. The shift is profound: we're no longer just treating numbers on a blood test—we're treating the heart, the kidneys, and the whole person. This article explores how SGLT2 inhibitors are reshaping the future of heart failure care and improving outcomes in ways no one predicted a decade ago.